Teriparatide

Summary

Teriparatide (CHEMBL525610) is an approved protein (ATC H05AA02) targeting PTH1R and PTH2R; indicated across 12 conditions including osteoporosis and postmenopausal osteoporosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: H05AA02
• Targets: 2 (PTH1R, PTH2R)
• Indications: 12 conditions
• Clinical trials: 139

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL525610
Name	Teriparatide
Type	Protein
Max phase	4
ATC	H05AA02

Also known as: Bonsity, Forsteo, Forteo, Kauliv, Livogiva, LY 333334, LY-333334, LY333334, Movymia, Qutavina, Sondelbay, Teriparatida

Patent coverage: 1,562 distinct patent families (3,549 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 2,474 (70%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTH1R	PTH1 receptor	Full agonist	7.4	0.1%	Q03431
PTH2R	PTH2 receptor	Full agonist	7.8	0.2%	P49190

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Parathyroid hormone/parathyroid hormone-related peptide receptor.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTH1R	10.1	IC50	0.08	nM	CHEMBL_ACT_18533014
PTH1R	9.52	EC50	0.3	nM	CHEMBL_ACT_3302306
PTH1R	9	EC50	1	nM	CHEMBL_ACT_3302307
PTH1R	8.6	EC50	2.5	nM	CHEMBL_ACT_18532990

Target pathways

Aggregated over 2 target gene(s): PTH1R, PTH2R.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Class B/2 (Secretin family receptors)	2	PTH1R, PTH2R
G alpha (s) signalling events	2	PTH1R, PTH2R

Dominant GO biological processes

GO term	Targets
cell surface receptor signaling pathway	2
G protein-coupled receptor signaling pathway	2
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	2
signal transduction	2
skeletal system development	1
in utero embryonic development	1
chondrocyte differentiation	1
osteoblast development	1
intracellular calcium ion homeostasis	1
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
cell population proliferation	1
positive regulation of cell population proliferation	1
negative regulation of cell population proliferation	1

Indications & clinical

Indications

12 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoporosis	4	MONDO:0005298	EFO:0003882
postmenopausal osteoporosis	4	MONDO:0008159	EFO:0003854
bone fracture	3	MONDO:0005315	EFO:0003931
hip fracture	3	MONDO:0005327	EFO:0003964
osteoarthritis, knee	2	MONDO:0005416	EFO:0004616
radius fracture	2	MONDO:0005325	EFO:0003957
neurogenic arthropathy	2	MONDO:0001935	EFO:1001378
hypoparathyroidism	2	MONDO:0001220	EFO:0009451
osteogenesis imperfecta	2	MONDO:0019019	MONDO:0019019

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 139.

Phase distribution

Phase	Trials
PHASE4	40
PHASE3	30
PHASE2	29
Not specified	24
PHASE1	14
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04522622	PHASE4	RECRUITING	Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
NCT04589819	PHASE4	ENROLLING_BY_INVITATION	Fracture Recovery for Returning to Duty (Teriparatide STRONG)
NCT05151484	PHASE4	ACTIVE_NOT_RECRUITING	Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
NCT06264609	PHASE4	ENROLLING_BY_INVITATION	Precision Medicine Approach for Osteoporosis - Follow Up Study
NCT06558188	PHASE4	RECRUITING	Combined Anabolic Therapy
NCT00035256	PHASE4	COMPLETED	Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
NCT00079924	PHASE4	COMPLETED	Effects of Teriparatide in Postmenopausal Women With Osteoporosis
NCT00131469	PHASE4	COMPLETED	Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
NCT00191425	PHASE4	COMPLETED	2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
NCT00239629	PHASE4	COMPLETED	Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
NCT00259298	PHASE4	COMPLETED	Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis
NCT00446589	PHASE4	TERMINATED	The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density
NCT00532545	PHASE4	COMPLETED	Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
NCT00557310	PHASE4	COMPLETED	A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
NCT00826228	PHASE4	COMPLETED	Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
NCT00887354	PHASE4	COMPLETED	A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
NCT00927186	PHASE4	COMPLETED	Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
NCT01105832	PHASE4	COMPLETED	Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?
NCT01153425	PHASE4	COMPLETED	µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
NCT01166958	PHASE4	COMPLETED	Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?
NCT01173081	PHASE4	UNKNOWN	The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures
NCT01292252	PHASE4	COMPLETED	Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion
NCT01293292	PHASE4	COMPLETED	Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
NCT01360424	PHASE4	COMPLETED	Teriparatide Treatment in Patients With Inherited Osteoporosis
NCT01400516	PHASE4	COMPLETED	Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
NCT01430104	PHASE4	COMPLETED	A Study of Teriparatide in Japanese Osteoporosis Patients
NCT01535027	PHASE4	COMPLETED	Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis
NCT01705587	PHASE4	COMPLETED	Fracture (FX) Improvement With Teriparatide: FiX-IT Study
NCT01709110	PHASE4	COMPLETED	VERtebral Fracture Treatment Comparisons in Osteoporotic Women
NCT01734824	PHASE4	SUSPENDED	Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo
NCT01750086	PHASE4	COMPLETED	Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
NCT01753856	PHASE4	COMPLETED	Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
NCT02090244	PHASE4	COMPLETED	Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?
NCT02176382	PHASE4	COMPLETED	Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
NCT02416271	PHASE4	COMPLETED	The Forteo Alendronate Comparator Trial
NCT02955056	PHASE4	UNKNOWN	Ankle Fractures Treated With Teriparatide
NCT03472846	PHASE4	COMPLETED	MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis
NCT04026256	PHASE4	COMPLETED	Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
NCT04241211	PHASE4	UNKNOWN	Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial
NCT06061354	PHASE4	UNKNOWN	Teriparatide on Maxillary Sinus Floor Osseointegration

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
ABALOPARATIDE	ChEMBL	Phase 4 (approved)	PTH1R
Belzutifan	PubChem	Approved	PTH1R